Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from ESSA Pharma ( (EPIX) ).
On September 30, 2025, a class action complaint was filed against ESSA Pharma Inc. in California, alleging breach of contract and promissory estoppel related to disclosures made in an August 14, 2025 Form 8-K. The complaint involves individuals and entities who purchased shares on August 25, 2025, prior to a company press release. ESSA Pharma intends to defend the lawsuit vigorously, but the outcome and potential losses are currently uncertain.
The most recent analyst rating on (EPIX) stock is a Hold with a $2.25 price target. To see the full list of analyst forecasts on ESSA Pharma stock, see the EPIX Stock Forecast page.
Spark’s Take on EPIX Stock
According to Spark, TipRanks’ AI Analyst, EPIX is a Neutral.
ESSA Pharma’s overall score reflects significant financial challenges with no revenue and ongoing losses. Technical indicators provide some positive signals, but caution is advised due to potential overbought conditions. The negative P/E ratio and lack of dividends further underline investment risks.
To see Spark’s full report on EPIX stock, click here.
More about ESSA Pharma
Average Trading Volume: 6,595,908
Technical Sentiment Signal: Sell
Current Market Cap: $10.28M
See more insights into EPIX stock on TipRanks’ Stock Analysis page.